Ocular Therapeutix, a Bedford, MA-based developer of ophthalmic therapeutic products, secured additional financing in its Series D round.
The amount of the transaction was not disclosed.
Backers included Baxter Ventures, which acquired a minority equity stake in the company, and Ascension Health Ventures, which led the round.
Led by Amar Sawhney, president and CEO, Ocular Therapeutix Ocular uses its proprietary hydrogel technology to develop drug-eluting punctum plugs for treatment of glaucoma and post-operative inflammation and pain, injectable depots for back-of-the-eye diseases, and ReSure Sealant for sealing clear corneal incisions following lens implantation surgery.
The company intends to use the capital to further develop its sustained release drug programs and support the commercial launch of the ReSure Sealant in the United States following FDA approval of the device.
FinSMEs
10/06/2013